The jury also found the infringing sales were made willfully. The Court may increase the final damage amount in light of the willfulness verdict. The Court also set a schedule to consider an injunction against Life Technologies for their sales of infringing products.

In November 2011 the Court’s ruling on Summary Judgment confirmed the validity of Promega Short Tandem Repeat (STR) patents, and found direct infringement by Life Technologies due to their sale of STR kits.

"The Court’s ruling and the jury award confirm the value of Promega STR technology and its contributions to genetic analysis in the fields of research and molecular diagnostics," says Bill Linton, Promega CEO.

Promega’s pioneering STR technology is used worldwide in a number of applications for genetic analysis beyond forensics and paternity testing, including genetic research, cell line authentication, bone marrow transplantation monitoring, forensic training, and various types of cancer analysis.